Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $200000.0.

  • Aligos Therapeutics' Depreciation & Amortization (CF) fell 3333.33% to $200000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $927000.0, marking a year-over-year decrease of 2869.23%. This contributed to the annual value of $1.0 million for FY2024, which is 3581.25% down from last year.
  • Per Aligos Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $200000.0 for Q3 2025, which was down 3333.33% from $300000.0 recorded in Q2 2025.
  • In the past 5 years, Aligos Therapeutics' Depreciation & Amortization (CF) ranged from a high of $800000.0 in Q2 2021 and a low of $200000.0 during Q1 2025
  • For the 5-year period, Aligos Therapeutics' Depreciation & Amortization (CF) averaged around $462789.5, with its median value being $400000.0 (2023).
  • Over the last 5 years, Aligos Therapeutics' Depreciation & Amortization (CF) had its largest YoY gain of 0.0% in 2024, and its largest YoY loss of 4325.0% in 2024.
  • Aligos Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $719000.0 in 2021, then decreased by 29.62% to $506000.0 in 2022, then decreased by 20.95% to $400000.0 in 2023, then tumbled by 43.25% to $227000.0 in 2024, then decreased by 11.89% to $200000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $200000.0 for Q3 2025, versus $300000.0 for Q2 2025 and $200000.0 for Q1 2025.